000134641 001__ 134641
000134641 005__ 20250129092426.0
000134641 0247_ $$2doi$$a10.1007/s11307-013-0621-3
000134641 0247_ $$2pmid$$apmid:23456885
000134641 0247_ $$2ISSN$$a1536-1632
000134641 0247_ $$2ISSN$$a1860-2002
000134641 0247_ $$2WOS$$aWOS:000321972500013
000134641 037__ $$aFZJ-2013-02758
000134641 041__ $$aENG
000134641 082__ $$a610
000134641 1001_ $$0P:(DE-Juel1)131691$$aKroll, Tina$$b0$$eCorresponding author$$ufzj
000134641 245__ $$aSuitability of [18F]Altanserin and PET to Determine 5-HT2A Receptor Availability in the Rat Brain: In Vivo and In Vitro Validation of Invasive and Non-Invasive Kinetic Models
000134641 260__ $$aAmsterdam [u.a.]$$bElsevier Science$$c2013
000134641 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1378707244_1314
000134641 3367_ $$2DataCite$$aOutput Types/Journal article
000134641 3367_ $$00$$2EndNote$$aJournal Article
000134641 3367_ $$2BibTeX$$aARTICLE
000134641 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000134641 3367_ $$2DRIVER$$aarticle
000134641 500__ $$3POF3_Assignment on 2016-02-29
000134641 520__ $$aPURPOSE: While the selective 5-hydroxytryptamine type 2a receptor (5-HT2AR) radiotracer [(18)F]altanserin is well established in humans, the present study evaluated its suitability for quantifying cerebral 5-HT2ARs with positron emission tomography (PET) in albino rats. PROCEDURES: Ten Sprague Dawley rats underwent 180 min PET scans with arterial blood sampling. Reference tissue methods were evaluated on the basis of invasive kinetic models with metabolite-corrected arterial input functions. In vivo 5-HT2AR quantification with PET was validated by in vitro autoradiographic saturation experiments in the same animals. RESULT: Overall brain uptake of [(18)F]altanserin was reliably quantified by invasive and non-invasive models with the cerebellum as reference region shown by linear correlation of outcome parameters. Unlike in humans, no lipophilic metabolites occurred so that brain activity derived solely from parent compound. PET data correlated very well with in vitro autoradiographic data of the same animals. CONCLUSION: [(18)F]Altanserin PET is a reliable tool for in vivo quantification of 5-HT2AR availability in albino rats. Models based on both blood input and reference tissue describe radiotracer kinetics adequately. Low cerebral tracer uptake might, however, cause restrictions in experimental usage.
000134641 536__ $$0G:(DE-HGF)POF2-333$$a333 - Pathophysiological Mechanisms of Neurological and Psychiatric Diseases (POF2-333)$$cPOF2-333$$fPOF II$$x0
000134641 588__ $$aDataset connected to CrossRef, juser.fz-juelich.de, PubMed,
000134641 7001_ $$0P:(DE-Juel1)131679$$aElmenhorst, David$$b1$$ufzj
000134641 7001_ $$0P:(DE-Juel1)138474$$aMatusch, Andreas$$b2$$ufzj
000134641 7001_ $$0P:(DE-Juel1)131711$$aWedekind, Franziska$$b3$$ufzj
000134641 7001_ $$0P:(DE-Juel1)131712$$aWeißhaupt, Angela$$b4
000134641 7001_ $$0P:(DE-Juel1)133864$$aBeer, Simone$$b5$$ufzj
000134641 7001_ $$0P:(DE-Juel1)131672$$aBauer, Andreas$$b6$$ufzj
000134641 773__ $$0PERI:(DE-600)2079211-6$$a10.1007/s11307-013-0621-3$$n4$$p456-467$$tMolecular imaging & biology$$v15$$x1860-2002$$y2013
000134641 8564_ $$uhttps://juser.fz-juelich.de/record/134641/files/FZJ-2013-02758.pdf$$yRestricted$$zPublished final document.
000134641 909CO $$ooai:juser.fz-juelich.de:134641$$pVDB
000134641 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)131691$$aForschungszentrum Jülich GmbH$$b0$$kFZJ
000134641 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)131679$$aForschungszentrum Jülich GmbH$$b1$$kFZJ
000134641 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)138474$$aForschungszentrum Jülich GmbH$$b2$$kFZJ
000134641 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)131711$$aForschungszentrum Jülich GmbH$$b3$$kFZJ
000134641 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)131712$$aForschungszentrum Jülich GmbH$$b4$$kFZJ
000134641 9101_ $$0I:(DE-Juel1)ZEA-2-20090406$$6P:(DE-Juel1)133864$$aZentralinstitut für Elektronik$$b5$$kZEA-2
000134641 9101_ $$0I:(DE-Juel1)INM-2-20090406$$6P:(DE-Juel1)133864$$aMolekulare Organisation des Gehirns$$b5$$kINM-2
000134641 9101_ $$0I:(DE-Juel1)ZEA-2-20090406$$6P:(DE-Juel1)133864$$aZentralinstitut für Elektronik$$b5$$kZEA-2
000134641 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)133864$$aForschungszentrum Jülich GmbH$$b5$$kFZJ
000134641 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)131672$$aForschungszentrum Jülich GmbH$$b6$$kFZJ
000134641 9132_ $$0G:(DE-HGF)POF3-579H$$1G:(DE-HGF)POF3-570$$2G:(DE-HGF)POF3-500$$aDE-HGF$$bKey Technologies$$lDecoding the Human Brain$$vAddenda$$x0
000134641 9131_ $$0G:(DE-HGF)POF2-333$$1G:(DE-HGF)POF2-330$$2G:(DE-HGF)POF2-300$$3G:(DE-HGF)POF2$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lFunktion und Dysfunktion des Nervensystems$$vPathophysiological Mechanisms of Neurological and Psychiatric Diseases$$x0
000134641 9141_ $$y2013
000134641 915__ $$0StatID:(DE-HGF)0040$$2StatID$$aPeer review unknown
000134641 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR
000134641 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000134641 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000134641 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000134641 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000134641 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000134641 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000134641 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000134641 9201_ $$0I:(DE-Juel1)INM-2-20090406$$kINM-2$$lMolekulare Organisation des Gehirns$$x0
000134641 9201_ $$0I:(DE-Juel1)ZEA-2-20090406$$kZEA-2$$lZentralinstitut für Elektronik$$x1
000134641 980__ $$ajournal
000134641 980__ $$aVDB
000134641 980__ $$aUNRESTRICTED
000134641 980__ $$aI:(DE-Juel1)INM-2-20090406
000134641 980__ $$aI:(DE-Juel1)ZEA-2-20090406
000134641 981__ $$aI:(DE-Juel1)PGI-4-20110106
000134641 981__ $$aI:(DE-Juel1)ZEA-2-20090406